STAGE III BLADDER CANCER AJCC V8
Clinical trials for STAGE III BLADDER CANCER AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new STAGE III BLADDER CANCER AJCC V8 trials appear
Sign up with your email to follow new studies for STAGE III BLADDER CANCER AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Bladder cancer breakthrough? immunotherapy plus Chemo-Radiation shows promise in lymph Node-Positive patients
Disease control OngoingThis study tests whether adding the immunotherapy drug durvalumab to standard chemotherapy and radiation can improve outcomes for people with stage III bladder cancer that has spread to nearby lymph nodes. About 95 adults will receive either chemoradiation alone or chemoradiation…
Matched conditions: STAGE III BLADDER CANCER AJCC V8
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 15, 2026 10:42 UTC
-
Promising combo targets tough bladder cancer
Disease control OngoingThis study tests a combination of two drugs, tazemetostat and pembrolizumab, in 30 people with advanced bladder cancer that has spread. The goal is to find the best dose and see if the combo works better than pembrolizumab alone. Participants must have had prior chemotherapy that…
Matched conditions: STAGE III BLADDER CANCER AJCC V8
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 15, 2026 10:29 UTC
-
Bladder cancer drug combo trial halted before enrolling a single patient
Disease control TerminatedThis study aimed to test two treatments for muscle-invasive bladder cancer in patients who cannot receive the standard chemotherapy drug cisplatin. The treatments were erdafitinib (a targeted pill) alone or combined with atezolizumab (an immunotherapy). The goal was to see if the…
Matched conditions: STAGE III BLADDER CANCER AJCC V8
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 15, 2026 10:27 UTC
-
New combo aims to stall advanced bladder cancer
Disease control OngoingThis study tests whether adding cabozantinib to avelumab (an immunotherapy) helps keep metastatic urothelial cancer from progressing after initial chemotherapy. About 654 adults with advanced bladder, kidney, or ureter cancer that has spread will receive either the combo or avelu…
Matched conditions: STAGE III BLADDER CANCER AJCC V8
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 13, 2026 16:03 UTC
-
New drug cocktail shows promise for Hard-to-Treat cancers
Disease control OngoingThis early-phase study tests a combination of two or three drugs (cabozantinib, nivolumab, and sometimes ipilimumab) in people with advanced genitourinary cancers that have spread. The main goals are to find the safest doses and understand side effects. About 152 adults with vari…
Matched conditions: STAGE III BLADDER CANCER AJCC V8
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 13, 2026 16:00 UTC
-
New combo aims to tame immunotherapy side effects in advanced cancers
Disease control OngoingThis study tests whether adding tocilizumab to standard immunotherapy (ipilimumab and nivolumab) can reduce severe side effects in people with advanced melanoma, lung, or bladder cancer. About 35 participants will receive the combination to see if it is safer and still effective.…
Matched conditions: STAGE III BLADDER CANCER AJCC V8
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 13, 2026 15:59 UTC
-
New hope for tough bladder cancers: drug targets DNA repair flaws
Disease control TerminatedThis study tests a drug called olaparib in people with advanced bladder or other genitourinary cancers that have specific DNA-repair defects. Olaparib works by blocking a protein that cancer cells need to repair their damaged DNA, which may stop the cancer from growing. The trial…
Matched conditions: STAGE III BLADDER CANCER AJCC V8
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 12, 2026 13:40 UTC
-
New combo shows promise for Tough-to-Treat bladder cancer
Disease control OngoingThis study tests whether adding the chemotherapy drug eribulin to the immunotherapy atezolizumab works better than atezolizumab alone for people with advanced bladder or urinary tract cancer who cannot take the standard chemotherapy cisplatin. About 72 adults with cancer that has…
Matched conditions: STAGE III BLADDER CANCER AJCC V8
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 06, 2026 16:02 UTC
-
Can a gene test tell who will benefit from immunotherapy?
Knowledge-focused OngoingThis study looks at whether certain genetic changes in tumors can help predict how well the immunotherapy drug nivolumab works for people with advanced bladder cancer that has spread. Researchers are focusing on two genes, ARID1A and KDM6A, and a protein called CXCL13. The goal i…
Matched conditions: STAGE III BLADDER CANCER AJCC V8
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated May 11, 2026 20:48 UTC